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“The missing ingredient”: the patient
perspective of health related quality of life
in bronchiectasis: a qualitative study
Emily K. Dudgeon1, Megan Crichton2 and James D. Chalmers2*
Abstract
Background: Bronchiectasis is a heterogeneous disease which affects quality of life. Measuring symptoms and
quality of life has proved challenging and research is limited by extrapolation of questionnaires and treatments
from other diseases. The objective of this study was to identify the major contributors to quality of life in
bronchiectasis and to evaluate existing health related quality of life questionnaires in bronchiectasis.
Methods: Eight adults with bronchiectasis participated in one to one semi-structured interviews. These were
recorded and transcribed verbatim. Thematic analysis was used to identify core themes relevant to disease burden
and impact. Participant views on current health related quality of life questionnaires were also surveyed.
Results: Bronchiectasis symptoms are highly individual. Core themes identified were symptom burden, symptom
variation, personal measurement, quality of life and control of symptoms. Themes contributing to quality of life
were: social embarrassment, sleep disturbance, anxiety and modification of daily and future activities. Evaluation of
4 existing questionnaires established their individual strengths and weaknesses. A synthesis of the participants’
perspective identified desirable characteristics to guide future tool development.
Conclusions: This qualitative study has identified core themes associated with symptoms and quality of life in
bronchiectasis. Current treatments and quality of life tools do not fully address or capture the burden of disease in
bronchiectasis from the patients’ perspective.
Keywords: Bronchiectasis, Symptoms, Endpoints, Questionnaires, Qualitative
Background
Bronchiectasis is a chronic respiratory disease charac-
terised by cough, sputum production and frequent chest
infections [1, 2]. These symptoms impact health related
quality of life (HRQL). HRQL questionnaires have be-
come a useful tool for measuring the impact of disease
on patients’ lives and are essential to assess new treat-
ments in clinical trials [3–5]. HRQL questionnaires have
been developed for respiratory conditions such as
COPD, asthma and chronic cough [6–9]. There is some
overlap between symptoms of bronchiectasis and those
of COPD and asthma, and two of these HRQL question-
naires (St George’s Respiratory Questionnaire and
Leicester Cough Questionnaire) have been validated for
use in bronchiectasis. [3, 7]. However it was not until
2014 that a HRQL questionnaire designed specifically
for bronchiectasis was published [10]. There are no large
comparative studies to determine which is the best
HRQL questionnaire for bronchiectasis.
The quality of life bronchiectasis questionnaire (QoL-B)
was developed in the context of a clinical trial of an in-
haled antibiotic and has not been tested widely in broad
populations of patients with bronchiectasis [11].
In recent years, there has been a shift away from a
traditional model of research where doctors or those
working in the pharmaceutical industry decide on the
best outcome measure when assessing new treatments.
The patient led model of research recognises the value
in patient involvement at every stage of clinical research,
and best practices have now been identified [12]. There
have been a series of unsuccessful trials in bronchiec-
tasis. Treatments that are widely used in clinical
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practice, and believed to be effective by clinicians and
patients, may give only small changes in questionnaires,
perhaps because we are unable to effectively measure
what matters to patients with bronchiectasis [13–16].
A major limitation affecting all bronchiectasis research is
that tools, approaches, questionnaires and treatments have
generally been extrapolated from other diseases. There
have been few studies specifically addressing the opinions,
experiences and needs of patients with bronchiectasis.
Bronchiectasis is a distinct, heterogeneous condition in
its own right [17]. Quality of life in particular is deeply
personal and specific to an individual. Patients’ quality of
life may be determined by more than simply the number
and frequency of physical symptoms but also by social,
psychological and other personal factors [4–9].
In view of the importance of health related quality of
life questionnaires for understanding bronchiectasis dis-
ease burden and as an outcome in clinical trials, we con-
ducted a qualitative study to determine what contributes
to quality of life in bronchiectasis patients and to gather
patient views and opinions on how existing question-
naires reflect their quality of life. Finally we present a
synthesis of bronchiectasis patients’ evaluation of exist-
ing health related quality of life questionnaires, including
the identification of desirable characteristics, with the
aim of guiding development of more patient focussed,
responsive and meaningful HRQL tools in future.
Methods
We performed a qualitative study of patients with bron-
chiectasis attending a regional specialist clinic at
Ninewells Hospital in Dundee, UK.
The inclusion criteria were: A clinical diagnosis of bron-
chiectasis confirmed by CT scanning, an ability to com-
municate in English, respiratoy symptoms that are caused
by the primary diagnosis of bronchiectasis. Key exclusion
criteria were: Inability to give informed consent; diagnosis
of cystic fibrosis, severe COPD or severe asthma. The
study was approved by the North West Ethics Committee-
approval number 16-NW-0100. All patients provided
written informed consent for participate.
Study interviews
The study consisted of a single in depth semi-structured
interview approximately one hour in length. Interviews
explored the nature, variation and impact of symptoms,
and the value of existing questionnaires as outlined
below. Interviews were audio-recorded and transcribed
verbatim. The interviewer was not involved in the clin-
ical care of the participants, and was trained in qualita-
tive methodology but did not have experience in
bronchiectasis. This was desirable to avoid conscious or
unconscious biases determined by prior experience with
bronchiectasis patients.
Analysis
Transcripts were analysed by the researchers and com-
mon themes were identified by thematic analysis. Fol-
lowing Strauss and Corbin (1998) text was analysed line
by line [18].
Responses were initially coded and grouped according
to the research objectives [19]. Common themes and re-
sponses were identified. The researchers modified their
coding and groups according to participant responses.
Interviews were participant driven, with the researcher
attending to understanding participants’ perspectives
from their point of view and using terminology common
to participants identified through the interviews. Sample
size was determined empirically, and was terminated at
participant 8 after reaching data saturation, in which no
new themes were identified.
The primary outcome of the study was to understand
the symptom burden of bronchiectasis and the key de-
terminants of quality of life. Secondary objectives were
to evaluate those symptoms that change most frequently
with exacerbations. Finally the study aimed to evaluate
how well existing questionnaires captured participants’
symptoms and quality of life, and the accessibility and
ease of use of questionnaires from a patient perspective.
The interview schedule which addresses each of these
objectives is shown in Table 1.
Questionnaires
Participants were presented with the questionnaires at
least 24 h before the interview in order to have time to be-
come familiar with and to complete the questionnaires.
The questionnaires selected for use in this study were
based on those identified in a systematic review of the
literature as being used in bronchiectasis studies to
evaluate symptoms or quality of life. These were
St. Georges Respiratory Questionnaire [3]
Quality of life bronchiectasis questionnaire version 3.1 [4]
Leicester Cough Questionnaire [7]
COPD assessment test [20]
Table 1 Interview outline
Symptom burden
What daily symptoms of bronchiectasis do you experience?
How do symptoms vary from day to day?
Is there a way to quantify changes- how do participants express
differences in how you are feeling (to doctors and to other patients)?
Exacerbations
What changes when you have an exacerbation?
What are the key symptoms that lead you to seek medical help?
Existing questionnaires
How well do these reflect your symptoms and the changes in your
symptoms?
Do you find the questionnaires easy to understand and answer?
How could you improve them?
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The St George’s Respiratory Questionnaire is a 50 item
tool with 2–5 responses per item (mean 2.5), 5 A4 pages
in length, giving a score of 0–100 points where 0 is no
impairment of quality of life and 100 is maximum im-
pairment. We note that there are 3 versions each with a
different recall time (1 month, 3 months and 1 year),
and the 3 month version was used in this study.
Quality of Life Bronchiectasis questionnaire is a 37
item tool with 2–6 responses per item (mean 4.1), 3 A4
pages in length, giving a score from 0 to 100 in each of 8
domains (respiratory symptoms, physical, role, emo-
tional and social, vitality, health perceptions, treatment
burden) and overall, where 0 is maximum impairment of
quality of life and 100 is no impairment. It has a recall
time of 1 week.
Leicester Cough Questionnaire is a 19 item tool with 7 re-
sponses per item on one A4 page, giving a score of 1–7 for
each of 3 domains- physical, psychological and social and a
total score of 3–21 with a higher score indicating minimal
impairment on quality of life. It has a 24 h recall time.
COPD Assessment Test is an 8 item tool with 6 nu-
merical responses per item, on one A4 page, giving a
score out of 40. A higher score suggests a greater impact
on quality of life. It has no specified recall time.
People living with bronchiectasis are referred to as pa-
tients and those who were interviewed for this study will
be referred to as participants.
Results
Eleven consecutive patients were invited to participate
and 8 interviews were carried out (5 female, 3 male).
The mean age was 72 (63–80). 4 had idiopathic bronchi-
ectasis, 2 had post-infective bronchiectasis. 1 participant
had co-existing COPD and 1 participant had co-existing
mild asthma (Table 2).
Thematic analysis of the interviews identified 5 key
determinants of symptom burden and quality of life.
Although our pre-specified analysis had intended to con-
sider exacerbation impact separately from stable disease
burden, our interviews revealed that participants
regarded exacerbations as an integral part of daily dis-
ease impact. Participants did not regard exacerbations as
a separate state from stable disease, but rather a con-
tinuum where daily symptoms become more severe or
persistent. Participants defined an exacerbation as a
worsening of symptoms, and recognised that this means
they need to seek medical help, however, sometimes pa-
tients do not seek medical help and try to self-manage.
In addition, all participants reported that exacerbations
impacted on daily quality of life even when “well” be-
cause of anxiety around exacerbations and the modifying
of activity and future plans due to risk of exacerbations
(Fig. 1).
Therefore exacerbations have been included in the fol-
lowing analysis as part of symptom burden. Table 3 shows
an example of the analysis whereby individual responses
were coded and then grouped into common themes.
The themes included were symptom burden, symptom
variation, personal measurement of symptoms, quality of
life and control. Symptom burden, symptom variation,
and quality of life were pre-specified terms while per-
sonal measurement of symptoms and control were
added based on consistent reporting by participants.
Theme 1: Symptom burden
A combination of cough, breathlessness and sputum
production was present in all participants although the
relative importance of each of these symptoms was
highly variable when describing the impact on their
quality of life.
Participant 4 “So, yeah, that, bronchiectasis, its, the
biggest thing is breathlessness.”
Participant 5 “The main one is that I, I cough a lot,
and I cough a lot of phlegm up, erm I’m also very, I
feel very short of breath sometimes.”
5/8 described chest tightness as a prominent symptom
in addition to breathlessness, cough and sputum
production.
Participant 7 “I have like a film forms across my chest.”
Additional symptoms that were reported were de-
creased energy levels (7/8), swallowing difficulties (3/8)
and hoarse voice (2/8).
Table 2 Participant characteristics
Characteristics N (%) or median (IQR)
N 8
Age- mean-range 72 (range 63–80)
Gender 5/8 (62.5%) female
Smoking history 6/8 (75%) never smokers
FEV1% predicted (mean-sd) 71.6% (24.4)
Bronchiectasis severity index (mean-sd) 8.6 (4.4)
Cause of bronchiectasis
Idiopathic 4 (50%)
Post-infective 2 (25%)
Sjogrens syndrome 1 (12.5%)
Ulcerative colitis 1 (12.5%)
Exacerbations per year (mean-sd) 1.8 (1.3)
Pseudomonas aeruginosa infection 3 (38%)
Long term macrolide use 4 (50%)
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Exacerbations were commonly (7/8) described as an
increase in symptom burden accompanied by a feeling
of being generally unwell.
Participant 1 “Erm, just general feeling not good, you
know, and tired, and erm breathless, erm a lot more
phlegm, using my inhaler a lot more”
Another participant described their exacerbations
much more in terms of change in character of cough
and increased sputum purulence, without necessarily
feeling generally unwell.
Increased sputum purulence is regarded by guidelines
as a core symptom of exacerbation. In this cohort,
change in sputum colour was mentioned as a key symp-
tom of exacerbation in only 4/8 participants. Participants
described changes in sputum in many different ways
using taste, volume, viscosity and colour with each giv-
ing different weight to each character.
Participant 7 “The mucus gets really tacky and it
doesnae (does not) clear”
Theme 2: Symptom variation
Participants (5/8) commonly experienced diurnal vari-
ation in their symptoms. For some participants
symptoms were worse in the morning, while for others
they were worse in the afternoon or evening.
Participant 6 “I don’t seem to have a problem until
about 4 o clock in the afternoon… Yeah I do tend to
avoid, meeting people you know, between four [pm]
and six [pm].”
Environmental factors such as the weather, smoke,
dust and paint also affected participants’ symptoms.
Participant 7 “I like, like going to watch the football,
but if it, if it’s a damp rainy cold night then I’m no
going. I’ll just say nah because I’ll feel really
horrendous the next day.”
There was no characteristic pattern to participants’
symptoms with the diurnal variation being highly
individual.
Theme 3: Personal measurement of symptoms
During the interviews it became clear that participants
monitor their symptoms in different ways. Participants
often expressed this in terms of the difference between a
good day and a bad day. Most participants (6/8) had
their own individual way of measuring how they are on
any given day.
Interviewer: is there anything else that you can
measure how bad you’re feeling on one specific day?
Participant 1: “It’s a strange one. My bra gets tight.
[laughs]”.
Participant 3 “I know I’m getting an infection if it
[phlegm] goes through a colour change and my pulse
rate goes up. My pulse rate is normally about 58/60
and that goes 70/75.”
Some participants (4/8) know when an exacerbation is
coming on because of symptoms that consistently occur
at the onset.
Table 3 Example of the coding and grouping approaches for
analysis
Participant information Coding Common theme
“I have like a film forming across
my chest”
Chest
tightness
Symptom
burden
“Coughing usually starts about twelve
O’Clock and it doesn’t have any rhyme
or reason”
Diurnal
variation
Symptom
variation
“Right, if somebody comes round to
your house, you get a visitor who goes
‘I’m not feeling well’ then I just say
‘well go away, just go, stay away
from me’.”
Social anxiety Quality of life
“how do you define moderate
difficulty and a little difficulty”
Questionnaire
answers
Questionnaires
Fig. 1 Core themes and sub themes identified from interviews
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Participant 2 “When I have an exacerbation, yes, I tend
first of all to start getting hot and cold flushes, …I then
start to become dizzy. I start to cough a lot more.”
The other participants had more heterogeneous, unpre-
dictable events without characteristic symptoms at onset.
Theme 4: Quality of life
All of the participants agreed that the disease had a
major impact on their quality of life. Impacts on quality
life were diverse, taking in social embarrassment associ-
ated with cough and sputum, sleep disturbance, modifi-
cation of activities and holiday plans, and anxiety or
concern about developing exacerbations.
Participants feel embarrassed about sputum produc-
tion in public.
Participant 5 “I’m worried about that [coughing when
talking to someone] because 1) I don’t like to do it 2)
they might think its unhygienic and erm 3) I do think
its unhygienic myself.”
Participants feel they have to explain their symptoms.
Participant 4 “I have come out of church a couple of
times and it upsets people because they think is she
going to die out there or whatever.”
Participant 5 “whoever it is will think you’re giving
them the bug of death or something you know.”
Symptoms also cause participants to avoid certain
situations.
Participant 7 “I wouldnae (would not) want to go to
the pictures or a theatre… It would spoil other
people’s enjoyment.”
Symptoms during the night can cause significant sleep
disturbance, with several participants sleeping in separ-
ate rooms to their partner so as not to disturb them.
Participant 2 “I do cough a lot…especially at night
time trying to get to sleep. That, erm, is a concern for
me, not to unduly disturb my wife.”
Symptom burden and seasonal and diurnal symptom
variation has forced many participants to modify their
daily activities.
Participant 7 “as I say you can’t go in the winter
months you cannae go out the walking that you do so
you’re confined to the house a wee bitty more, so you
get a wee bitty fed up so you munch a wee bitty more
and you put on a bit more weight that you’ve just
took off.”
The unpredictability of an exacerbation causes signifi-
cant anxiety for participants and their families, particu-
larly around planning travel and family events. For
example, the word anxiety was mentioned 21 times by a
single participant.
Theme 5: Control
Lack of control over symptoms was consistently re-
ported (5/8) as a key impact of the disease. Control was
frequently (7/8) mentioned in interviews and only one
participant felt they were always in control of their con-
dition. One participant cited control as the one thing
they would change about the condition if they could.
Participant 4 “ I don’t have control over my cough…I
mean you can grab the bottle of water and hope it
shuts up for a minute or two but it’s not, you know, I
don’t feel I control it all.”
Regular exercise (4/8) and having antibiotics at home
to self-manage exacerbations made participants feel that
they had more control over their condition.
Participant 1 (regarding self-management with antibi-
otics at home) “And you feel as if you’ve got control. You
know, that you can do something. Cos if the doctor’s sur-
gery is closed over the weekend, what do you do?”
Exacerbations can take away the feeling of having con-
trol which can cause anxiety.
Participant 2 “Well I feel very dependent on others.
And that to some extent is debilitating. It’s almost
humiliating at times.”
Evaluation of questionnaires
Evaluation of existing questionnaires identified desirable
and undesirable characteristics (Fig. 2) for HRQL
questionnaires used in bronchiectasis. Participants com-
mented on the extent to which questions were under-
standable and reflective of their experience, the extent to
which answer options gave them scope to express how
they felt and the layout of questions in terms of ease of
use and time taken for completion. Participants varied in
their knowledge of medical terms. For example, com-
monly used terms like wheeze were considered jargon
and poorly understood by many participants.
Figure 2 shows the aspects of questionnaires that par-
ticipants did and did not value.
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Referring to specific questionnaires:
SGRQ- Participants reported that true and false answer-
ing method was very clear but gave too limited scope for
answering questions, and suggested the use of a baseline.
The questionnaire requires a recall time of 3 months
which concerned some participants.
Participant 5 “again, the true and false, is just, it’s not,
you’re not giving enough information to people.”.
Participant 4 “Over the past 3 months, in an average
week how many good days? Its, it’s a long time to
remember”
QolB- This was the most commonly preferred ques-
tionnaire (6/8 participants). The number of multiple
choice answers were viewed favourably when compared
to the true and false of the SGRQ and the seven choices
of the LCQ, but participants felt the questions were
sometimes ambiguous. While some participants felt that
seven choices were too many, others viewed the in-
creased number of options as favourable.
Participant 7 “During the past week indicate how
often you have felt well. Again relative to what?
What’s your baseline? The word “well”, is
meaningless. It is its meaningless. No I’m no as well
as I should be but am I as bad as I could be? No so
what’s well?”
CAT- The layout was praised for its simplicity and
ease of reading but there was disagreement as to
whether the visual scale from 0 to 5 was easy or difficult
to answer.
Participant 2 “I like the layout… It’s very visual.”
Participant 4 “I found it very difficult to judge erm,
which one, sort of, represented it”
LCQ- The layout was criticised but compared with the
other questionnaires, the LCQ’s answers have numbers
and phrases which was considered favourable.
Participant 6 “Well it gave you more choices, there
was, there was seven choices but it gave you much
more, you could more accurately describe what your
symptoms were.”
Overall, the strengths and weaknesses of the different
questionnaires from the bronchiectasis patient’s perspec-
tive is summarised in Fig. 3.
Discussion
This qualitative study of symptom burden and quality of
life in bronchiectasis has identified a disconnect between
the classic symptoms of bronchiectasis (such as sputum
production, purulence and exacerbations) and the im-
pact on patients’ quality of life. Our analysis suggests
Fig. 2 Participants’ perspective on different health related quality of life and symptom questionnaires in bronchiectasis
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that what most strongly affects a patient’s quality of life
is highly personal to the individual, but includes an abil-
ity to feel in control of their symptoms, to achieve nor-
mal sleep and take part in social activities without
embarrassment. Anxiety and fear of exacerbations had a
major impact on quality of life.
These findings are important for clinical care, because
many of these are aspects that are not frequently explored
in a doctor-patient consultation. They are important for
the development of new therapies because treatments
aiming to improve quality of life need to be capable of ad-
dressing the major determinants of quality of life [21, 22].
Quality of life tools are used in clinical practice and in
clinical trials to measure disease impact and response to
therapy. We conducted what to the best of our know-
ledge is the only comparative “preference” study relating
to quality of life tools in bronchiectasis. This analysis
found that each of the questionnaires have different
strengths and weaknesses. Discussion of these has
allowed us to develop a framework for the “perfect”
quality of life tool from a bronchiectasis patient’s per-
spective. We identified that the quality of life bronchiec-
tasis questionnaire was the most frequently preferred
questionnaire from a patient perspective. It should be
noted that the clinical value of a questionnaire includes
its repeatability, responsiveness and clinical utility and
that patient preference and ease of use is only one aspect
of the evaluating a questionnaire [3, 4].
An interesting finding was disparity between how pa-
tients describe symptoms and how they are evaluated in
questionnaires. A question may try to quantify exercise
limitation in terms of mild or moderate difficulty, whereas
patients do not think about symptoms in this way.
Patients were consistently more focussed on “change from
baseline” or differences between what they can achieve
and what they want to achieve, which is highly individual.
It is intuitively correct, and was expressed by the majority
of patients, that you cannot accurately quantify something
without a frame of reference. Patients find it much more
straightforward to say they are “worse than usual” than to
say they have “moderate difficulty” carrying out a task,
without a frame of reference for how much difficulty a
person without bronchiectasis might experience.
It is not surprising that bronchiectasis symptoms and
quality of life determinants are heterogeneous because
the disease itself is heterogeneous. It is caused by a
range of underlying disorders, affecting all age groups
and having a highly variable clinical course [23–26]. This
emphasises one of the key findings of this research- it
may be impossible to fully capture disease impact with
categorical scales that do not account for patient’s highly
variable baseline symptoms, expectations and co-
morbidities [22, 26]. As mentioned above, patients re-
ported that anchoring questions within patients own
baseline function could provide a solution to this hetero-
geneity. An example of an anchored question would be:
Fig. 3 Graphical illustration of the strengths and weaknesses of the different QOL questionnaires based on participants’ evaluation
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How is your breathlessness at the moment?
 My breathless is much better than normal
 My breathless is better than normal
 My breathless is normal for me
 My breathlessness is worse than normal for me
 My breathlessness is much worse than normal
compared to an unanchored question such as:
Walking up a flight of stairs makes me feel breathless.
 True
 False
Our study suggested the “perfect” questionnaire would
use both anchored and unanchored questions to estab-
lish the patients baseline with a second question or set
of questions to establish change from baseline.
There are similarities between our findings and those
of qualitative studies in COPD and asthma in terms of
symptom burden, anxiety, the benefit of exercise, control
and self monitoring [27, 28]. It is interesting to note that
the worry of asthma attacks is similar to that of exacer-
bations in bronchiectasis in impacting quality of life
even when patients are not experiencing symptoms. Al-
though it was not identified as a major theme, control
was discussed in both the COPD and asthma studies.
Similar to the current study, it was mentioned in a num-
ber of contexts: for example in asthma patients not be-
ing able to control the external environment leading to
exposure to triggers and in COPD patients trying to take
control of their condition.
Self monitoring differed between asthma and bronchiec-
tasis patients. Whereas asthma patients are able to use the
objective measure of peak expiratory flow rate, bronchiec-
tasis patients have no objective measurement of their
symptoms. As a result, self monitoring tends to be more
subjective, and more individualised in bronchiectasis.
The COPD study reported that objective measurement
of severity does not correlate with patient experience. The
authors hypothesise that this may be attributable to varia-
tions in coping strategies and self management, and that
patients with poor quality of life scores may be most suit-
able for non pharmacological interventions. The use of
data measuring patient reported impact on quality of life
in guiding management is an interesting suggestion, par-
ticularly as medicine and clinical research transition from
a traditional paternalistic style to a patient led model.
Another qualitative study compared 3 quality of life
questionnaires used in asthma [29]. Participants identi-
fied missing and irrelevant content when assessing ques-
tionnaires as weaknesses. Similar to the current study,
confusing questions were identified as a weakness in sev-
eral questionnaires and the questionnaire preferred by
participants was one that covered both medical and psy-
chosocial impact of disease. This is in line with our find-
ings on how bronchiectasis impacts quality of life.
Therefore our findings are consistent with work in
other chronic respiratory conditions but with disease
specific features because of the subtle differences in the
combination of symptoms present in each disease.
Limitations of this study must be acknowledged.
This is a qualitative study and as is typical of such
studies the sample size is small. This study is single
centre and it is known that bronchiectasis can be
quite heterogeneous across different healthcare
systems. Nevertheless our patient population is
typical/representative in terms of demographics of
European bronchiectasis cohorts. [26, 30, 31] A small
number of patients had previously completed ques-
tionnaires such as the QOL-B as part of clinical re-
search studies and so we acknowledge prior
experience as a potential source of bias. The length
of interview and timing of interviews during working
hours may have skewed the population towards older,
retired participants. Nevertheless, as the average age
of bronchiectasis patients is 65–70 years, we do not
regard this as major bias [31, 32].
Conclusions
This study has characterised bronchiectasis symptom bur-
den and its impact on quality of life and identified scope for
improving existing health related quality of life question-
naires. [32] The framework we have developed can be used
to evaluate future HRQL questionnaires for bronchiectasis.
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